{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T15:31:14Z","timestamp":1751038274556},"reference-count":5,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The use of blood transfusions to improve anemia resulting from sickle cell disease (SCD) is often limited by alloimmunization, which occurs due to exposure to incompatible antigen present on donor red blood cells (RBCs). This complication occasionally manifests as delayed hemolytic transfusion reactions (DHTRs) that cause hemolysis of the recipient's own RBCs and can lead to fatal anemia. In this case study, we report a patient with SCD who experienced a DHTR following chronic transfusion and was successfully treated with voxelotor, an orally administered sickle hemoglobin (HbS) polymerization inhibitor for the treatment of SCD. Laboratory tests following admission indicated pan\u2010reactivity in antigens, and a rare donor registry was used to locate acceptable units. The patient experienced the DHTR 3\u2009days after admission, which limited laboratory tests due to profound hemolysis. Alternative treatments were limited, and phenotypically matched units were incompatible, so voxelotor was selected as a last\u2010resort treatment. Following initiation of voxelotor 1500\u2009mg, the patient's hemoglobin levels returned to baseline (6\u00a0g\/dl) within 10\u2009days, with clinical improvements. This report provides evidence regarding the use of voxelotor in the treatment of profound anemia where other treatments could be unsafe or unavailable.<\/jats:p>","DOI":"10.1111\/ejh.13830","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T13:05:13Z","timestamp":1658149513000},"page":"586-589","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe"],"prefix":"10.1111","volume":"109","author":[{"given":"Mica","family":"Ferlis","sequence":"first","affiliation":[{"name":"Division of General Internal Medicine Virginia Commonwealth University Medical Center  Richmond Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thokozeni","family":"Lipato","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine Virginia Commonwealth University Medical Center  Richmond Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan D.","family":"Roseff","sequence":"additional","affiliation":[{"name":"Department of Pathology Virginia Commonwealth University Medical Center  Richmond Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wally R.","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine Virginia Commonwealth University Medical Center  Richmond Virginia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30193-9"},{"key":"e_1_2_5_3_1","unstructured":"National Heart Lung and Blood Institute.Evidence\u2010Based Management of Sickle Cell Disease. Expert Panel Report 2014. Accessed May 13 2021.https:\/\/www.nhlbi.nih.gov\/health-topics\/all-publications-and-resources\/evidence-based-management-sickle-cell-disease-expert-0"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15328"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903212"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16068"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13830","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13830","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T09:00:44Z","timestamp":1692694844000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1111\/ejh.13830"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13830","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]},"assertion":[{"value":"2022-04-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}